Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Cash from Operations (2016 - 2025)

Sangamo Therapeutics has reported Cash from Operations over the past 16 years, most recently at 24403000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 24403000.0 for Q4 2025, down 628.23% from a year ago — trailing twelve months through Dec 2025 was 97208000.0 (down 44.79% YoY), and the annual figure for FY2025 was 97208000.0, down 44.79%.
  • Cash from Operations for Q4 2025 was 24403000.0 at Sangamo Therapeutics, up from 28498000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for SGMO hit a ceiling of 11759000.0 in Q3 2024 and a floor of 68550000.0 in Q1 2021.
  • Median Cash from Operations over the past 5 years was 51552500.0 (2021), compared with a mean of 42303350.0.
  • Biggest five-year swings in Cash from Operations: plummeted 1127.33% in 2021 and later soared 124.86% in 2024.
  • Sangamo Therapeutics' Cash from Operations stood at 52714000.0 in 2021, then fell by 8.22% to 57049000.0 in 2022, then increased by 11.41% to 50538000.0 in 2023, then surged by 93.37% to 3351000.0 in 2024, then plummeted by 628.23% to 24403000.0 in 2025.
  • The last three reported values for Cash from Operations were 24403000.0 (Q4 2025), 28498000.0 (Q3 2025), and 18158000.0 (Q2 2025) per Business Quant data.